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Therapeutic Class Management (TCM) Workgroup
•	 A	multidisciplinary	TCM	workgroup	was	created	consisting	of		
pharmacists,	child	psychiatrists,	and	a	social	worker.
•	 Retrospective	case	review	is	conducted	on	a	daily	basis	to	provide	an	
increased	level	of	clinical	expertise	and	prescriber	outreach	as	appropriate.
•	 Cases	are	discussed	weekly	among	workgroup	members.
•	 Member cases reviewed by TCM include:
–	 Recent	psychiatric	hospitalization	
–	 History	of	severe	risk	of	harm	to	self	or	others
–	Member	age	<3	years	old
–	 Behavioral	health	regimens	with	≥5	medications
–	Members	not	engaged	in	psychosocial	interventions	
•	 Workgroup responsibilities include:
–	 	Clinical	discussions	regarding	treatment	plans
–	 	Prescriber	outreach	to	encourage	evidence-based	prescribing	practices
–	 	Referral	of	members	to	a	behavioral	health	program	that	assists	in	
integrating	care	and	providing	psychosocial	interventions
•	 TCM	cases	are	tracked	and	monitored	to	assess	the	impact	of	workgroup	
interventions	on	treatment	plans	and	integration	of	care.
METHODS
The	PBHMI	is	a	prospective	utilization	management	policy	that	
was	developed	for	specific	behavioral	health	medications	and	
polypharmacy	combinations	that	have	limited	evidence	of	safety	
and	efficacy	in	order	to	ensure	appropriate	medication	use.
CONCLUSIONS
•	 The	PBHMI	focuses	on	safe	and	effective	behavioral		
health	medication	use	in	members	<18	years	old.
•	 Age	restrictions	(<3	and	<6	years	old)	were	successfully		
implemented	on	November	24,	2014.
•	 Polypharmacy	restrictions	will	be	implemented	in	February	2015.
•	 Prior	authorization	criteria	was	designed	to	reflect	evidence-based	
medicine	and	expert	consensus.
•	 A	multidisciplinary	TCM	workgroup	was	created	to	further	evaluate	
member	cases	as	a	method	for	continuous	quality	assurance,	
improvement,	and	transparency.
•	 Prescriber	outreach	was	conducted	through	different	avenues	and	
include	targeted	prescriber	telephone	calls	to	assist	in	successful	
implementation	and	to	facilitate	uninterrupted	member	care.
FUTURE PLANS
•	 The	initiative	will	be	evaluated	by	internal	quality	assurance	programs	
to	determine	effects	on	prescribing	trends	and	member	outcomes.
•	 The	development	of	prescriber	education	materials	relating	to	
behavioral	health	medication	prescribing	trends	would	be	valuable		
to	the	goal	of	the	initiative.
•	 Expansion	of	the	initiative	for	all	pediatric	members	of	the	Medicaid	
program	(e.g.,	members	in	managed	care	organizations)	is	underway.
BACKGROUND
• Behavioral health medication utilization in the pediatric 
population has increased over several years. Use	of	these	
medications	and	polypharmacy	regimens	among	the	Medicaid	pediatric	
population	is	a	major	concern.	Oversight	and	monitoring	of	behavioral	
health	medication	prescribing	practices	is	necessary	to	ensure		
appropriate	care.
•	 Several	studies	investigated	trends	in	behavioral	health	
medication use in youth. 
–	 An	increase	in	behavioral	health	medication	polypharmacy	regimens	has	
been	observed	in	the	pediatric	population.1,2
–	 The	utilization	of	antipsychotic	agents	in	pediatric	patients	and	in	
combination	with	other	behavioral	health	medications	has	increased.1-3
•	 The	U.S.	Government	Accountability	Office	(GAO)	reported	
concerns with behavioral health medications prescribed  
in children.
–	December 2011 Report:	“Department	of	Health	and		
Human	Services	guidance	could	help	states	improve	oversight		
of	psychotropic	prescriptions.”4
–	Highest	rate	of	behavioral	health	medication	utilization	in	MA	
compared	to	other	states	(FL,	MI,	OR,	TX).
–	 In	MA,	39.1%	of	foster	care	children	were	prescribed	behavioral	
health	medications	compared	to	10.2%	of	those	not	in	foster	care.
–	December 2012 Report:	“Concerns	remain	about	appropriate	
services	for	children	in	Medicaid	and	Foster	Care.”5
–	Behavioral	health	regimens	with	≥5	medications	(20	to	39%	in	foster	
care	children	compared	to	5	to	10%	in	those	not	in	foster	care).
–	Antipsychotic	utilization	in	children	covered	by	Medicaid	was		
twice	as	likely	compared	to	those	privately	insured.
OBJECTIVE
To	describe	the	implementation	of	the	Pediatric	Behavioral	Health	Medication	
Initiative	(PBHMI),	a	safety	initiative	that	oversees	the	utilization	of	behavioral	
health	medications	for	pediatric	members	in	a	state	Medicaid	Program.
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*	Computer	coding	technology	integrates	medical	data	to	assist	in	drug	utilization	review.	
*	For	all	restrictions,	refills	on	prescriptions	written	before	11/24/2014	were	grandfathered	into	
the	initiative.	
*	Provisional	approvals	and	emergency	supply	overrides	ensure	member	care	will	not	be	disrupted.	
Prescriber	outreach	is	conducted	on	provisional	approvals	and	potential	denials.
Outreach Methods Prior to Implementation
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Initiative Implementation Timeline
•	 December 2011 - 2012:
	 GAO	reports	published
•	 April 2014:
	 Psychopharmacology	Expert	
Advisory	Workgroup	Meetings	
to	review	clinical	criteria
•	 January -  February 2015:
	 Staff	refresher	trainings,	targeted	
prescriber	telephone	outreach	
(polypharmacy	restrictions),	
implementation	of	PBHMI	
polypharmacy	restrictions		
in	February	2015
•	 May - July 2014:
	 Development	of	internal	guideline,	
prior	authorization	forms,	and	
computer	coding
•	 August - October 2014:	
	 Retrospective	data	analyses	to	predict	the	impact	of	
the	initiative	and	methods	for	prescriber	outreach,	
development	of	staff	training	materials,	meetings	
with	state	and	prescriber	organizations	to	discuss		
the	initiative
•	 August 2014:
 Development	of	PBHMI	
webpage	materials
•	 November 2014:	
	 State	approval,	advocacy	
group	meeting,	prescriber	
mailings,	targeted	prescriber	
telephone	outreach	(age	
restrictions),	staff	trainings,		
implementation	of	PBHMI	
age	restrictions	on	
November	24,	2014
•	 January 2013 - March 2014:
 Discussions	with	the	DMH	and	DCF	
psychopharmacology	workgroups	and	
advocacy	groups,	literature	review,	and	
development	of	clinical	criteria
•	 December 2014:	
	 TCM	Workgroup	created	and	
member	case	review	began		
(and	continues	through	present)
2011 - 2012 2013 2014 2015
For Polypharmacy  
Restrictions
•	 Prescribers	of	behavioral	health	
medication	polypharmacy	regimens		
for	≥15	members	<18 years old
MassHealth Drug  
List Webpage
•	 Clinical	Document
•	 Therapeutic	class	table,	criteria,		
and	prior	authorization	forms
•	 Frequently	Asked	Questions
Electronic  
Communications
•	 E-prescriber	Letter		
(N=280 subscribers)
•	 Pharmacy	Facts		
(N=1,100 pharmacies)
Targeted Prescriber Telephone Outreach
Prescriber Letter Mailings  (N=14,352)
For Age Restrictions
•	 Prescribers	of	behavioral	health	
medications	for	≥5	members		
<6 years old
•	 Prescribers	for	members	<3 years old 	
•	 Prescribers	for	all	members	<18 years old 
•	 Massachusetts	and	border	states	only	
Prior Authorization (PA) Requirements
PA	requirements	for	members	<3	years	old
Any	pharmacy	claim	for	an	alpha2	agonist	or	cerebral	stimulant
PA	requirements	for	members		<6	years	old
Any	pharmacy	claim	for	an	antipsychotic,	antidepressant,	atomoxetine,	benzodiazepine,	
buspirone,	hypnotic,	or	mood	stabilizer	
PA	requirements	for	members		<18	years	old
Type	of	Polypharmacy Number	of	Prescriptions	and	Duration
Antidepressant 2	or	more	for	≥60	days	within	a	90	day	period
Antipsychotic 2	or	more	for	≥60	days	within	a	90	day	period
Benzodiazepine 2	or	more	for	≥60	days	within	a	90	day	period
Cerebral	stimulant 2	or	more	for	≥60	days	within	a	90	day	period
Mood	stabilizer 3	or	more	for	≥60	days	within	a	90	day	period
Behavioral	health	medication	 4	or	more	within	a	60	day	period
Total	number	of	prescribers	=	79 Total	number	of	prescribers	=	123
